Building buzz for Impact 2020: The MassBio Strategic Report, we continued our #Impact2020 Twitter Chat Series last night. In the chat we focused on the evolution & future of early-stage funding in life sciences with moderator John Hallinan, Chief Business Officer at MassBio, and guest moderator David Berry, Partner at Flagship Ventures.
From pharma-based venture funds to advocacy group-directed research to crowd-funding, we’re in the midst of a sea change in how emerging biotechs find funding and address capital challenges. The IPO window reopened in 2013 but how long can we expect it to stay open? With a significant decline in seed stage funding, are Massachusetts’ good ideas being funded? How do we continue to support fledgling companies that need startup money for early research or proof-of-concept?